IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

NCT07122687 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: IBI363
DRUG: Carboplatin
DRUG: Keytruda

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.